Vincerx Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	12.85	11.73	111.56	61.79	0.03
Short-Term Investments	0	40.8	0	0	0
Cash & Cash Equivalents	12.85	52.53	111.56	61.79	0.03
Cash Growth	-75.53%	-52.92%	80.55%	247068.00%	-
Receivables	1.04	1.37	0	0	0
Other Current Assets	0.84	2.06	0.28	1.32	0
Total Current Assets	14.73	55.96	111.84	63.11	0.03
Property, Plant & Equipment	2.33	3.24	4.18	0	0
Other Long-Term Assets	1.16	0.08	1.65	0.08	0
Total Long-Term Assets	3.48	3.32	5.84	0.08	0
Total Assets	18.22	59.29	117.68	63.19	0.03
Accounts Payable	2.5	4.07	2.02	5.51	0
Current Debt	1.16	1.02	0.74	0	0
Other Current Liabilities	1.95	4.07	11.16	32.31	0
Total Current Liabilities	5.61	9.16	13.92	37.81	0
Long-Term Debt	1.34	2.41	3.44	0	0
Other Long-Term Liabilities	0.05	0.05	0	0	0
Total Long-Term Liabilities	1.39	2.46	3.44	0	0
Total Liabilities	7	11.62	17.36	37.81	0
Total Debt	2.5	3.44	4.17	0	0
Debt Growth	-27.18%	-17.68%	-	-	-
Retained Earnings	-159.11	-118.96	-55.97	-16.67	-0
Comprehensive Income	0.01	-0.03	-0.02	0	0
Shareholders' Equity	11.22	47.67	100.32	25.38	0.02
Net Cash / Debt	10.35	49.09	107.39	61.79	0.03
Net Cash / Debt Growth	-78.91%	-54.29%	73.79%	247068.00%	-
Net Cash Per Share	0.49	2.33	6.25	11.77	0.02
Working Capital	9.13	46.81	97.92	25.3	0.02
Book Value Per Share	0.53	2.27	5.84	4.83	0.02

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).